Target populations of oligodendrocyte precursor cells and methods of making and using same

• US 10,400,214 B2
• Filed: 11/17/2017
• Issued: 09/03/2019
• Est. Priority Date: 12/23/2008
• Status: Active Grant

• Current Assignee: BOCO Silicon Valley, Inc.
• Original Assignee: BOCO Silicon Valley, Inc.
• Inventors: Capela, Alexandra, Uchida, Nobuko
• Primary Examiner(s): Hayes, Robert C
• Application Number:
  US15/816,323
• Publication Number:
  US 20180187148A1
• Time in Patent Office: 655 Days
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: C12N 2501/105 Insulin-like growth factors [IGF]
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2501/135 Platelet-derived growth factor [PDGF]
• CPC Class Codes: C12N 5/0622 Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells

Abstract

This application provides for enriched target populations oligodendrocyte precursor cells (OPCs) that can differentiate into oligodendrocytes. The target OPCs may be expanded and optionally subjected to conditions to induce their differentiation into oligodendrocytes. The target OPCs and their progeny are useful for the treatment of disease associated with demyelination of central nervous system axons.

Claims

1. A method of producing a population enriched for oligodendrocyte precursor cells comprising:

(a) contacting neural or neural derived cells comprising one or more multipotent central nervous system stem cell with an antibody that specifically binds to PDGFRα

; and

(b) selecting said neural or neural derived cells that are PDGFRα

^hi, wherein the selected cells are enriched for oligodendrocyte precursor cells as compared with the neural or neural derived cells.

2. The method of claim 1, wherein said neural or neural derived cells are obtained from a neurosphere culture or an adherent culture.

3. The method of claim 1, wherein the method further comprises the step of eliminating those cells that are PDGFRα

^lo/med.

4. The method of claim 1, wherein the method further comprises the step of eliminating cells that are CD105⁺.

5. The method of claim 4, wherein the oligodendrocyte precursor cells are PSA-NCAM^lo/−

.

6. The method of claim 4, wherein the oligodendrocyte precursor cells are A2B5^lo/−

.

7. The method of claim 4, wherein the oligodendrocyte precursor cells are CD133⁺.

8. The method of claim 7, wherein the oligodendrocyte precursor cells are A2B5^lo/−

.

9. The method of claim 8, wherein the oligodendrocyte precursor cells are PSA-NCAM^lo/−

.

10. The method of claim 1, wherein the oligodendrocyte precursor cells are CD105⁻

.

11. The method of claim 1, wherein the oligodendrocyte precursor cells are PSA-NCAM^lo/−

.

12. The method of claim 1, wherein the oligodendrocyte precursor cells are A2B5^lo/−

.

13. The method of claim 1, wherein the oligodendrocyte precursor cells are CD133⁺.